Actively Recruiting
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
Led by The Cooper Health System · Updated on 2025-07-01
140
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
Sponsors
T
The Cooper Health System
Lead Sponsor
S
Society of Vascular and Interventional Neurology
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?
CONDITIONS
Official Title
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Radiographic evidence of chronic subdural hematoma, including persistence of subdural blood more than 10 days after injury
- Presence of mixed density blood
- Presence of subdural membranes
- Ability to provide informed consent and HIPAA authorization
You will not qualify if you...
- Pregnant, breastfeeding, or unwilling to use contraception during the study
- Presence of other intracranial pathology besides subdural hematoma
- Known hypersensitivity to bevacizumab
- Radiographic evidence of mass effect
- Focal neurological deficits due to subdural hematoma
- Craniotomy or burr hole surgery within two weeks before subdural hematoma onset
- Secondary causes of cSDH other than trauma (e.g., vascular abnormalities or tumor)
- Need for emergency surgical evacuation
- Non-convexity chronic subdural hematoma
- Coagulation problems, including low platelet count or abnormal INR
- Contraindications to angiography or contrast allergy not manageable
- Active systemic infection or sepsis
- Contraindications to anesthetic agents used for sedation
- Life expectancy under six months due to other terminal conditions
- Premorbid modified Rankin score of 5 or higher
- Concurrent participation in another experimental therapy research study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cooper University Health Care
Camden, New Jersey, United States, 08103
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here